media – Page 586 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Enzychem Lifesciences Announces the FDA Orphan Drug Designation Granted to EC-18 on Acute Radiation Syndrome (ARS)

Enzychem Lifesciences, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS).
- Source: china-pharmacy
- 610
- February 1, 2018
ARS EC-18 FDA Orphan Drug Designation rare diseases
NICE becomes latest champion for digital health

NICE has become the latest organisation to champion digital health, recommending that the NHS should trial an online and mobile programme to treat depression.
- Source: Pharma Phorum
- 754
- February 1, 2018
Company Insight digital health EHR NICE
Seattle Genetics Snaps Up Cascadian in $614M Buyout Deal

The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
- Source: Biospace
- 472
- February 1, 2018
Cascadian HER2 Market Views merger-and-acquisition
U.K. Startup Medopad Signs Deals with Tencent and Ping An

London-based startup accompanying U.K. Prime Minister on trade mission
- Source: Bloomberg Technology
- 572
- February 1, 2018
AI China Company Insight digital health
BridgeBio Pharma Licenses Late-Stage Oncology Drug Infigratinib to Tackle FGFR-Driven Maladies; Establishes New Subsidiary QED Therapeutics with $65 Million in Initial Financing

BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
- Source: Prnewswire
- 621
- February 1, 2018
achondroplasia infigratinib (BGJ398) Market Views Novartis QED Therapeutics
Adverum Biotechnologies and Editas Medicine Extend Research Collaboration

Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced today an extension of its collaboration agreement with Editas Medicine, Inc. (Nasdaq:EDIT). The companies established this collaboration to explore the delivery of genome editing medicines to treat up to five inherited retinal diseases.
- Source: investors.adverum
- 476
- January 31, 2018
genome editing Market Views retinal diseases
FDA Calls Roche’s Autism Drug a Breakthrough

An experimental Roche drug designed to improve social interaction in people with autism scored the U.S. Food and Drug Administration’s Breakthrough Therapy Designation.
- Source: Biospace
- 733
- January 31, 2018
autism New Approvals
Russian researchers develop test strip to diagnose heart attack

Scientists at the National University of Science and Technology (NUST) MISIS in Russia have developed a new membrane test strip for quantitative immune chromatography rapid tests to rapidly and accurately detect an acute myocardial infarction by analysing blood for the presence of disease markers.
- Source: medicaldevice-network
- 549
- January 31, 2018
immune chromatography rapid test Researches
FDA steps up efforts at bringing about medical device cyber security

It is a disturbing, but true fact that medical devices are hacked. Medical devices have inbuilt software, and hackers try to breach this. Medical device cybersecurity is thus critical, because lack of it can bring harm to patients who use medical devices that come with software built into them.
- Source: COMPLIANCE4ALL14
- 648
- January 31, 2018
cybersecurity FDA medical device Policy
Five Prime Therapeutics Announces $25 Million Payment by Bristol-Myers Squibb for Cabiralizumab Development Milestone

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that a development milestone for cabiralizumab has been achieved, triggering a $25 million payment from Bristol-Myers Squibb Company (BMS) (BMY) under the license and collaboration agreement between the companies established in 2015. The milestone was triggered by initiation of a multi-arm Phase 2 clinical trial (NCT03336216), sponsored by Bristol-Myers Squibb Company, evaluating cabiralizumab and Opdivo® (nivolumab) with and without chemotherapy in patients with advanced pancreatic cancer. “Effective treatment for patients with pancreatic cancer remains a significant unmet need and is a cancer for which existing immunotherapies have not been successful to date,” said Helen Collins, M.D., Senior Vice President and Chief Medical Officer of Five Prime. “We are encouraged by the preliminary data presented at SITC 2017 and are pleased to see this trial underway.” The Phase 2 trial is expected to enroll approximately 160 ...
- Source: finance.yahoo
- 569
- January 31, 2018
Bristol-Myers Squibb cabiralizumab Opdivo

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.